Literature DB >> 3769763

Monitoring vancomycin therapy.

M J Rybak, S C Boike.   

Abstract

Vancomycin is an effective and widely used antistaphylococcal antibiotic. Despite several decades of use, however, our knowledge of the toxicologic and pharmacokinetic properties of vancomycin remains incomplete. This review summarizes current information regarding the adverse reactions and pharmacokinetics of vancomycin. Although there have been reports of side effects with vancomycin, these effects tend to be infrequent, easily managed, and reversible. Several methods for adjustment of vancomycin therapy have been recommended. The relationship between serum concentrations of vancomycin and the occurrence of ototoxicity or nephrotoxicity has not been well established. However, because of large interpatient variations in pharmacokinetic parameters, it seems preferable to individualize vancomycin therapy based on serum concentration data.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3769763     DOI: 10.1177/106002808602001003

Source DB:  PubMed          Journal:  Drug Intell Clin Pharm        ISSN: 0012-6578


  11 in total

1.  The serum vancomycin assay: A test of historic interest.

Authors:  S Shafran; J Conly
Journal:  Can J Infect Dis       Date:  1995-03

2.  Cost-ineffectiveness of serum vancomycin levels.

Authors:  B A Cunha; S S Mohan; N Hamid; B P McDermott; P Daniels
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-07       Impact factor: 3.267

3.  Vancomycin monitoring in children using bayesian estimation.

Authors:  Jennifer Le; Becky Ngu; John S Bradley; William Murray; Austin Nguyen; Lyn Nguyen; Gale L Romanowski; Tiana Vo; Edmund V Capparelli
Journal:  Ther Drug Monit       Date:  2014-08       Impact factor: 3.681

4.  Population pharmacokinetic analysis of vancomycin in patients with hematological malignancies.

Authors:  Dolores Santos Buelga; María del Mar Fernandez de Gatta; Emma V Herrera; Alfonso Dominguez-Gil; María José García
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

5.  Comparison of steady-state pharmacokinetics of two dosage regimens of vancomycin in normal volunteers.

Authors:  D P Healy; R E Polk; M L Garson; D T Rock; T J Comstock
Journal:  Antimicrob Agents Chemother       Date:  1987-03       Impact factor: 5.191

Review 6.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

7.  Pharmacokinetic/pharmacodynamic analysis of vancomycin in ICU patients.

Authors:  Maria del Mar Fernández de Gatta Garcia; Natalia Revilla; Maria Victoria Calvo; Alfonso Domínguez-Gil; Amparo Sánchez Navarro
Journal:  Intensive Care Med       Date:  2006-12-13       Impact factor: 17.440

8.  Population pharmacokinetic analysis of vancomycin using serum cystatin C as a marker of renal function.

Authors:  Akihiro Tanaka; Tetsuya Aiba; Takashi Otsuka; Katsuya Suemaru; Tatsuya Nishimiya; Tomoyoshi Inoue; Mitsuharu Murase; Yuji Kurosaki; Hiroaki Araki
Journal:  Antimicrob Agents Chemother       Date:  2009-11-23       Impact factor: 5.191

Review 9.  Teicoplanin in perspective. A critical comparison with vancomycin.

Authors:  R Janknegt
Journal:  Pharm Weekbl Sci       Date:  1991-08-23

10.  Vancomycin utilization evaluation at hematology-oncology ward of a teaching hospital in iran.

Authors:  Afsaneh Vazin; Aziz Japoni; Sakineh Shahbazi; Mohammad Ali Davarpanah
Journal:  Iran J Pharm Res       Date:  2012       Impact factor: 1.696

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.